FilingSEC EDGAR8-K
Oncolytics Biotech Announces Positive Preclinical Results for Pelareorep Combination Therapy
· SEC accepted
StagePreclinical
Filing content
The company reported positive preclinical results in a colorectal cancer model, demonstrating tumor growth reduction and biological compatibility between pelareorep and a pan-RAS inhibitor.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…